SCHEMBL1735688

SCHEMBL1735688

CNC(=O)c1cc(-c2ccccc2)nc(NCc2ccco2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
RAB9A P51151 3/20 0.52
KDM4E B2RXH2 3/20 0.52
POLB P06746 1/20 0.52
MAPK8 P45983 1/20 0.50
KMT2A Q03164 4/20 0.48
NPC1 O15118 2/20 0.48
EED O75530 1/20 0.48
KCNH3 Q9ULD8 1/20 0.47
TSHR P16473 4/20 0.47
NPSR1 Q6W5P4 2/20 0.46
MEN1 O00255 2/20 0.46
HSD17B10 Q99714 4/20 0.46
MAPK1 P28482 3/20 0.46
LMNA P02545 2/20 0.46
ALOX15 P16050 1/20 0.46
HTT P42858 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734611 0.86 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2RAB9AKDM4EPOLB
SCHEMBL1734442 0.85 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2RAB9AKDM4EPOLB
SCHEMBL1734290 0.79 TDP1 (0.65) SMN1; SMN2RAB9AKMT2ANPC1MEN1
SCHEMBL1734126 0.77 VCP (0.67)
SCHEMBL1735531 0.76 KDM4E (0.45) ALDH1A1SMN1; SMN2RAB9AKDM4EPOLB
SCHEMBL1734608 0.76 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2RAB9AKDM4EPOLB
SCHEMBL1734586 0.75 KDM4E (0.66) ALDH1A1SMN1; SMN2RAB9AKDM4EKMT2A
SCHEMBL1735687 0.73 KDM4E (0.43) ALDH1A1SMN1; SMN2RAB9AKDM4EPOLB
SCHEMBL13309939 0.70 PDE5A (0.59) ALDH1A1SMN1; SMN2KDM4EPOLBKMT2A
SCHEMBL10051966 0.69 CHEK1 (0.51) ALDH1A1SMN1; SMN2RAB9AKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
EP-1891018-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals, Inc. (US) 2008-02-27 EP claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
WO-2006127588-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-30 WO claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 ALDH1A1 2670/4885SMN1; SMN2 4832/4885RAB9A 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.